ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pacritinib

Also written as “Pacritinib”, “SB1518” and “CYP450 Cocktail and Transporter Substrates with Pacritinib”.

Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Leukemia, Myelomonocytic, Chronic · COVID-19 · Hodgkin Disease, led by 4 companies.

Drug pagePacritinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 18, 201318 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Swedish Orphan Biovitrumits history only122 open or runningphase 3since Jan 18, 2013Jan 18, 2013Dec 30, 2026phase 2 · NCT06782373
S*BIOits history only40 open or runningphase 2since Jul 20, 2008Jul 20, 2008none ahead
Takeda10 open or runningphase 2since Oct 21, 2015Oct 21, 2015none ahead
Theradexits history only11 open or runningphase 2since Jun 5, 2025Jun 5, 2025Jul 2028phase 2 · NCT07033598

Also a collaborator on its studies: PSI CRO, PPD DEVELOPMENT, LP, Covance, SGS and QPS-Qualitix.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2015First study: phase 2 study in Primary MyelofibrosisFirst studyNCT02584777

TargetBeta

“The citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
“Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor”ChEMBL 37, by rule

Studies

The one study Takeda leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02584777Primary Myelofibrosis2WithdrawnSep 30, 20170

How it is read

Names in the registry

  • “Pacritinib”, 13 entries
  • “SB1518”, 4 entries
  • “CYP450 Cocktail and Transporter Substrates with Pacritinib”, 1 entry
  • “Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib”, 1 entry
  • “Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.